2214MO Phase I basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein-targeting antibody-drug conjugate: Results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC)
Year: 2025
Type: article
Source: Annals of Oncology
Authors: J.J. Harding, J.H. Strickler, J. Henry, M.R. Sharma, S. Koganemaru, M. Passhak, D. Mahalingam, T. Golan, K.P. Papadopoulos, A. Hubert, A. Badu-Nkansah, M. Burns, R.R. Li, M.E. Blaney, M. Alshaer, M. Mehibel, R. Geva
Institutions: Memorial Sloan Kettering Cancer Center, Duke University, Duke Medical Center, National Cancer Centre Japan, National Cancer Center Hospital East, Rambam Health Care Campus, Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Sheba Medical Center, South Texas Accelerated Research Therapeutics, Hadassah Medical Center, AbbVie (United States), Tel Aviv Sourasky Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: AbbVie
OpenAlex ID: W4415941909